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Objectives: In adults, the incidence of S. pneumoniaeinfections and the related 
mortality increase with age and co-morbidities. The Belgian Superior Health Council 
recommends use of 13-valent pneumococcal conjugate vaccine (PCV13) in adults 
with elevated risk of pneumococcal diseases. PCV13 has recently proven effica-
cious in preventing pneumococcal pneumonia and invasive pneumococcal dis-
ease (IPD) in the elderly. We investigated the cost-effectiveness of vaccinating the 
65-84 y. old cohort (n= 862,188) that suffer from co-morbidities or immunosuppres-
sion MethOds: A cohort model with a Markov-type process was developed to 
project the lifetime risks and related costs of IPD and nonbacteremic pneumococcal 
pneumonia. Input data came from various sources (literature, existing databases, 
and observational studies) and were reviewed by a panel of Belgian experts. PCV13 
effectiveness was derived from the recently published CAPiTA clinical trial results 
for the first 5 years. Protection gradually declined thereafter to zero by year 16. 
Belgian National Health perspective was taken with costs and quality-adjusted life 
years (QALYs), discounted annually by 3% and 1.5%, respectively. Sensitivity analyses 
on key parameters were performed in order to test the robustness of model find-
ings. Results: 58% vaccination coverage with PCV13 in 65-84 year olds suffering 
from co-morbidities or immunosuppression is expected to prevent 6,798 cases of 
pneumococcal disease, and 911 disease-related deaths over lifetime compared to 
no vaccination. PCV13 vaccination cost was fully offset by reduction in disease-
related costs (€ 61 million), and thus was overall cost-saving. In the one-way sensi-
tivity analysis, results were most sensitive to PCV13 price and parameters related 
to inpatient pneumonia. In probabilistic sensitivity analysis, PCV13 dominated the 
no vaccination strategy in 97% of the simulations. cOnclusiOns: PCV13 vaccina-
tion of the 65-84 year-old cohort in Belgium would prevent a substantial number 
of cases and deaths from severe pneumococcal disease and be cost-saving from a 
healthcare perpective .
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Objectives: Herpes Zoster (HZ) and its most common complication, Post-Herpetic 
Neuralgia (PHN), are painful and debilitating conditions with an important burden 
for patients and society. A live-attenuated one-dose vaccine was licensed in 2006 
for the prevention of both HZ and PHN in adults 50+ years old and is currently 
recommended and part of vaccination calendars in several countries. The objec-
tive of this study was to assess the cost-effectiveness of zoster vaccination for the 
50+ population in Portugal. MethOds: An existing European Markov cohort model 
was adapted to the Portuguese healthcare setting. Health states considered are 
healthy, HZ, PHN, healthy post-HZ and death. HZ and PHN states are further split 
by pain severity (mild, moderate or severe). According to local guidelines, the cost-
effectiveness outcomes were assessed from the societal perspective for a public 
reimbursement at 37%. Analysis comparing a HZ vaccination for adults aged ≥ 50 
years with no vaccination was done. Input data were obtained from Portuguese 
sources whenever available. Results: The strategy of vaccinating adults 50+ years 
old showed an incremental cost-effectiveness ratio of 19.625€ per quality adjusted 
life year (QALY) gained from a societal perspective. The analysis showed cost-effec-
tiveness improvement with age with an ICER in the 65+ population of 15.517€ /QALY 
from the societal perspective. The probabilistic sensitivity analyses showed that 
for high levels of certainty (95%) the ICER does not exceed 25.000€ /QALY from the 
societal perspective. cOnclusiOns: Considering the generally acceptable thresh-
old, the present cost-effectiveness analysis demonstrates that HZ vaccination for 
adults 50+ years old in Portugal is a cost-effective strategy. Vaccine reimbursement 
would provide substantial health, social and economic benefits in the Portuguese 
health care context.
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Objectives: To estimate the cost-effectiveness of three candins (anidulafungin, 
caspofungin, and micafungin) and generic fluconazole in the treatment of non-neu-
tropenic adult patients with candidemia and/or invasive candidiasis (IC) in intensive 
care units (ICU) in Spain. MethOds: A decision tree model was performed. The 
success (clinical and microbiological response) and safety (hepatic and renal adverse 
effects) of first-line treatments were obtained from meta-analyses and systematic 
reviews of clinical trials. In the case of failure, a second-line treatment (liposomal 
amphotericin B after the candins, or one of the candins after fluconazole) was 
administered. The duration of the treatments (14 days total) was established by 
IDSA guidelines. The cost of the medications and renal toxicity were considered. 
Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations 
were carried out. Results: The total cost of the treatment of candidemia and/or 
invasive candidiasis with anidulafungin, caspofungin, micafungin, and flucona-
zole was € 5483, € 5968, € 6231, and € 2088, respectively. Anidulafungin was the 
dominant treatment (more effective, less expensive) compared to micafungin and 
above, and recently approved for 50 years and above. The aim of present study 
was to evaluate the cost-effectiveness of implementing HZ vaccination program 
for adults at age 50 years versus 60 years in Hong Kong from the perspective of 
society. MethOds: A Markov model was designed to compare the clinical and 
economic outcomes of a hypothetical cohort of 50-year-old adults with (1) no 
HZ vaccination, (2) vaccination at 50-year-old, and (3) vaccination at 60-year-old. 
Model inputs were retrieved from literature. HZ-associated total costs (direct and 
indirect costs) and quality-adjusted life years (QALYs) loss were outcome measures 
of the model. Sensitivity analyses were conducted to examine the robustness of 
model results. Results: In base-case analysis, the two vaccination strategies were 
more costly with less QALY loss than no vaccination. Comparing to no vaccination, 
incremental cost-effectiveness ratio (ICER) of vaccinating at 50 and 60 years old 
were HKD175,397 per QALY saved and HKD190,174 per QALY saved, respectively 
(USD1= HKD7.8). All-cause death rate and prevalence of HZ were two potential 
influential factors on the base-case results. In 10,000 Monte Carlo simulations, the 
probability of HZ vaccination at 50-year-old to be the preferred option was 98.2% 
of time, using the gross domestic product per capita in Hong Kong (HKD297,360) 
as threshold of willingness-to-pay. cOnclusiOns: HZ vaccination for adults aged 
50-year-old in Hong Kong seems to be the preferred option when compared to 
vaccination at 60-year-old and no vaccination.
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Objectives: In Germany, vaccination of infants with a 13-valent pneumococcal 
conjugate vaccine (PCV13) and of individuals > = 60 years with a 23-valent pneumo-
coccal polysaccharide vaccine (PPSV23) is recommended to prevent pneumococcal 
diseases. Recently, PCV13 was also approved for individuals > = 50 years. The study 
assesses the cost-effectiveness of four vaccination strategies targeting adults > = 60 
years in Germany: no vaccination, vaccination with PCV13 only, vaccination with 
PPSV23 only, and sequential-vaccination (PCV13+PPSV23). MethOds: A suscepti-
ble-infected-susceptible type model based on ordinary differential equations was 
developed to capture the dynamic transmission of pneumococcal carriage. The 
model compartments were further stratified by age- and pneumococcal serotype-
groups. Model parameters were either retrieved from the literature or obtained 
by fitting against local incidence data. The epidemiological impact of childhood 
PCV13-vaccination (herd and serotype replacement effects) on incidence and 
serotype mix among adults as well as components of the four adult vaccination 
strategies was implemented in the model. A health-economic model was built to 
compute the incremental cost-effectiveness ratios (ICER) per QALY using German 
cost data. The robustness of the model results was assessed through sensitivity 
analyses regarding uncertain input data. Results: In the base case, the ICER of 
PPSV23 vs. no vaccination was € 24,085/QALY. Immunization with PCV13 alone was 
dominated by PPSV23-vaccination. Sequential vaccination vs. PPSV23 vaccina-
tion resulted in € 400,528/QALY. Main reason for the higher ICERs of the latter two 
strategies was a sharp decline in PCV13-serotypes prevalence among adults as 
an indirect result of infant PCV13-vaccination. Sensitivity analyses identified the 
effectiveness of PPSV23 against non-invasive pneumococcal pneumonia to have a 
substantial impact on the model results and be a major source of uncertainty due 
to the heterogeneity in reported effectiveness/efficacy data. cOnclusiOns: From 
a health economic perspective, PPSV23 would be the preferred vaccine to be used 
for the prevention of pneumococcal disease in adults in Germany.
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Objectives: Assess the cost-effectiveness of the reinstatement (stopped in 2003) of 
an 18-month booster dose of diphtheria, tetanus and acellular pertussis (DTPa-18-
month) vaccine on the National Immunisation Program (NIP) in Australia, focusing 
on pertussis prevention. MethOds: The economic evaluation was conducted in 
two stages: (a) the annual epidemiological effect of the vaccination was assessed at 
steady state with an age-stratified, compartmental dynamic population model cali-
brated on Australian pertussis sero-incidence data, allowing estimation of under-
reporting of pertussis using published notification rates, (b) evaluation of total costs 
and quality adjusted life years (QALYs) associated with pertussis cases using a static 
decision tree model. Two scenarios were compared: the current DTP vaccination 
schedule (2, 4, 6 months; 4 years; 12 years) with and without DTPa-18-month (cov-
erage 83%; effectiveness 88%). Direct medical costs, from a payer perspective, and 
pertussis related QALYs lost were generated via data retrieved from the literature 
and Australian tariffs. A discount rate of 5% was applied to costs and outcomes, and 
a 100-year time horizon used. The pertussis cases, hospitalization, costs and QALYs 
were estimated and compared between strategies. One-way sensitivity analyses 
were conducted on the incremental cost-effectiveness ratio (ICER) by varying key 
parameters. Results: DTPa-18-month was projected to prevent 1.3 million symp-
tomatic pertussis cases; 2,762 hospitalizations; gaining 22,430 QALYs at an increased 
cost of $70,667,758. The predicted ICERs were; $54 per symptomatic pertussis case 
avoided, $3,151 per QALY gained, and $25,590 per hospitalization avoided. Most 
benefit was incurred by the target population, aged < 4 years. Infectiousness level, 
pertussis incidence rate, vaccine cost, administration fee and utility loss for unre-
ported cases were predicted to have the largest effect on the ICER. cOnclusiOns: 
Reintroduction of DTPa-18-month in the Australian NIP was demonstrated to be a 
cost-effective strategy.
